About this Journal Submit a Manuscript Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2013 (2013), Article ID 689142, 17 pages
http://dx.doi.org/10.1155/2013/689142
Review Article

Ginkgo biloba Extract for Patients with Early Diabetic Nephropathy: A Systematic Review

1Nephropathy Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China
2Key Unit of Methodology in Clinical Research, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China
3The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510405, China
4National Center for Design Measurement and Evaluation in Clinical Research, Guangzhou University of Chinese Medicine, Guangzhou 510405, China

Received 9 June 2012; Accepted 29 September 2012

Academic Editor: Benny Tan Kwong Huat

Copyright © 2013 Lei Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. T. Reutens and R. C. Atkins, “Epidemiology of diabetic nephropathy,” Contributions to Nephrology, vol. 170, pp. 1–7, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. C. E. Mogensen, C. K. Christensen, and E. Vittinghus, “The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy,” Diabetes, vol. 32, no. 2, pp. 64–78, 1983. View at Scopus
  3. S. Racki, L. Zaputovic, B. Vujicic, Z. Crncevic-Orlic, S. Dvornik, and Z. Mavric, “Comparison of survival between diabetic and non-diabetic patients on maintenance hemodialysis: a single-centre experience,” Diabetes Research and Clinical Practice, vol. 75, no. 2, pp. 169–175, 2007. View at Publisher · View at Google Scholar
  4. S. S. B. Mousavi, F. Hayati, M. J. A. Ansari et al., “Survival at 1, 3, and 5 years in diabetic and nondiabetic patients on hemodialysis,” Iranian Journal of Kidney Diseases, vol. 4, no. 1, pp. 74–77, 2010. View at Scopus
  5. A. I. Adler, R. J. Stevens, S. E. Manley, R. W. Bilous, C. A. Cull, and R. R. Holman, “Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64),” Kidney International, vol. 63, no. 1, pp. 225–232, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Vupputuri, G. A. Nichols, H. Lau, P. Joski, and M. L. Thorp, “Risk of progression of nephropathy in a population-based sample with type 2 diabetes,” Diabetes Research and Clinical Practice, vol. 91, no. 2, pp. 246–252, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Y. Li, L. Cui, and M. Cui, “Hot topics in chinese herbal drugs research documented in pubmed/medline by authors inside china and outside of china in the past 10 years: based on co-word cluster analysis,” Journal of Alternative and Complementary Medicine, vol. 15, no. 7, pp. 779–785, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. P.-C. Chan, Q. Xia, and P. P. Fu, “Ginkgo biloba leave extract: biological, medicinal, and toxicological effects,” Journal of Environmental Science and Health Part C, vol. 25, no. 3, pp. 211–244, 2007. View at Publisher · View at Google Scholar
  9. G. B. Kudolo, S. Dorsey, and J. Blodgett, “Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and Type 2 diabetic subjects,” Thrombosis Research, vol. 108, no. 2-3, pp. 151–160, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. G. B. Kudolo, D. Delaney, and J. Blodgett, “Short-term oral ingestion of Ginkgo biloba extract (EGb 761) reduces malondialdehyde levels in washed platelets of type 2 diabetic subjects,” Diabetes Research and Clinical Practice, vol. 68, no. 1, pp. 29–38, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Ninomiya, V. Perkovic, B. E. De Galan et al., “Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes,” Journal of the American Society of Nephrology, vol. 20, no. 8, pp. 1813–1821, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Welt, J. Weiss, R. Martin, T. Hermsdorf, S. Drews, and G. Fitzl, “Ginkgo biloba extract protects rat kidney from diabetic and hypoxic damage,” Phytomedicine, vol. 14, no. 2-3, pp. 196–203, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Tang, Z. Zhang, Y. Gao, Y. Wei, and L. Han, “Protective effects of serum containing Ginkgo biloba extract on glomerulosclerosis in rat mesangial cells,” Journal of Ethnopharmacology, vol. 124, no. 1, pp. 26–33, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. Q. Lu, X. X. Yin, J. Y. Wang, Y. Y. Gao, and Y. M. Pan, “Effects of Ginkgo biloba on prevention of development of experimental diabetic nephropathy in rats,” Acta Pharmacologica Sinica, vol. 28, no. 6, pp. 818–828, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Chen, Y. L. Ma, and B. J. Chen, “Effect of shuxuening on IL-18 in patients with early diabetic nephropathy,” China Pharmacy, vol. 21, no. 28, pp. 2645–2647, 2010 (Chinese).
  16. L. Chu, “The effect of valsartan combined with ginkgo bilolm extract in the treatment of early diabetic nephropathy,” Chinese Journal of Postgraduates of Medicine, vol. 33, no. 7, pp. 16–18, 2010 (Chinese).
  17. Y. D. Han, “The treatment with ginkgo leaf extract and dipyridamole injection and Lotensin for early diabetic nephropathy,” Shaanxi Journal of Traditional Chinese Medicine, vol. 29, no. 8, pp. 961–962, 2008 (Chinese).
  18. J. Z. Huang, X. P. Qiu, and J. Wang, “Plasma level of circulating endothelial cells in patients with early diabetic nephropathy and interventional treatment of ginkgo damole injection,” Chinese Journal of Clinical Pharmacology and Therapeutics, vol. 11, no. 11, pp. 1309–1312, 2006 (Chinese).
  19. Q. Li and L. Y. Han, “The effect of jinnaduo with monopril on early diabetic nephropathy,” Chinese Journal of Misdiagnostics, vol. 10, no. 15, p. 3572, 2010 (Chinese).
  20. X. S. Li, X. J. Fu, and X. J. Lang, “Effect of extract of Gingko biloba on soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in patients with early diabetic nephropathy,” Chinese Journal of Integrated Traditional and Western Medicine, vol. 27, no. 5, pp. 412–414, 2007 (Chinese). View at Scopus
  21. P. Y. Lu, “The effect of xingding injection on early diabetic nephropathy,” Zhejiang Journal of Integrated Traditional and Western Medicine, vol. 15, no. 8, pp. 470–471, 2005 (Chinese).
  22. J. Lu, “Effect of Ginkgo biloba extract injection on urinary microaibumin of early diabetic nephropathy,” Clinical Focus, vol. 20, no. 12, pp. 673–675, 2005 (Chinese).
  23. X. P. Qiu, “Clinical observation on the therapeutic effect of ginkgo damole injection in treating patients with early diabetic nephropathy,” Strait Pharmaceutical Journal, vol. 18, no. 4, pp. 144–146, 2006 (Chinese).
  24. Q. F. Quan, “The effect of ginkgo leaf extract and dipyridamole injection on early dibetic nephropathy,” Clinical Focus, vol. 18, no. 18, pp. 1059–1060, 2003 (Chinese).
  25. M. C. Tian, “The treatment of ginkgodipyidamolum to the early diabetic nephropathy,” Journal of Mathematical Medicine, vol. 22, no. 4, pp. 473–474, 2009 (Chinese).
  26. D. F. Wang, “The effect of Ginkgo flavone on PAI-1 of early dibetic nephropathy,” Clinical Focus, vol. 20, no. 15, pp. 882–883, 2005 (Chinese).
  27. H. J. Wang, “The effect of Ginkgo biloba extract on UET of diabetic nephropathy,” Journal of Shandong University of Traditional Chinese Medicine, vol. 28, no. 4, pp. 282–283, 2004 (Chinese).
  28. H. S. Zhang, “The effect of Ginkgo biloba to mAlb of early diabetic nephropathy,” Chinese Journal of Information on Traditional Chinese Medicine, vol. 16, no. 11, p. 66, 2009 (Chinese).
  29. L. Zhang, “Effect of Ginkgo biloba extract injection on urinary microalbumin excretion in patients with early diabetic nephropathy,” China Pharmacy, vol. 18, no. 30, pp. 2374–2375, 2007 (Chinese).
  30. S. Zhang, H. Y. Hu, X. Y. Wang, and G. H. Ding, “Effect of Xingding injection on thrombomodulin and von Willebrand factor in patients with diabetic nephropathy,” The Journal of Practical Medicine, vol. 22, no. 3, pp. 283–285, 2006 (Chinese).
  31. J. P. T. Higgins and S. Green, Cochrane Handbook For Systematic Reviews of Interventions Version 5. 0. 2, chapter 8, The Cochrane Collaboration, 2009, http://www.cochrane-handbook.org/.
  32. J. P. T. Higgins and S. Green, Cochrane Handbook For Systematic Reviews of Interventions Version 5. 0. 2, chaper 9. 2. 3 and 12. 4. 1, The Cochrane Collaboration, 2009, http://www.cochrane-handbook.org/.
  33. J. P. T. Higgins and S. Green, Cochrane Handbook For Systematic Reviews of Interventions Version 5. 0. 2, chapter 16. 6, The Cochrane Collaboration, 2009, http://www.cochrane-handbook.org/.
  34. Z. Wang, Y. H. Zhang, and Q. Q. Xu, “Several methods of publication bias evaluation,” Chinese Journal of Health Statistics, vol. 26, no. 5, pp. 539–541, 2009 (Chinese).
  35. M. T. James, B. R. Hemmelgarn, and M. Tonelli, “Early recognition and prevention of chronic kidney disease,” The Lancet, vol. 375, no. 9722, pp. 1296–1309, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. S. I. Hallan, E. Ritz, S. Lydersen, S. Romundstad, K. Kvenild, and S. R. Orth, “Combining GFR and albuminuria to classify CKD improves prediction of ESRD,” Journal of the American Society of Nephrology, vol. 20, no. 5, pp. 1069–1077, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. B. R. Hemmelgarn, B. J. Manns, A. Lloyd et al., “Relation between kidney function, proteinuria, and adverse outcomes,” Journal of the American Medical Association, vol. 303, no. 5, pp. 423–429, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Van Der Velde, P. E. De Jong, and R. T. Gansevoort, “Comparison of the yield of different screening approaches to detect chronic kidney disease,” Nephrology Dialysis Transplantation, vol. 25, no. 10, pp. 3222–3230, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Chronic Kidney Disease Prognosis, K. Matsushita, M. van der Velde et al., “Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis,” The Lancet, vol. 375, no. 9731, pp. 2073–2081, 2010.
  40. A. Ishani, G. A. Grandits, R. H. Grimm et al., “Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial,” Journal of the American Society of Nephrology, vol. 17, no. 5, pp. 1444–1452, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. A. H. Brantsma, S. J. Bakker, H. L. Hillege, D. De Zeeuw, P. E. De Jong, and R. T. Gansevoort, “Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion,” Nephrology Dialysis Transplantation, vol. 23, no. 12, pp. 3851–3858, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. H. H. Parving, H. Lehnert, J. Brochner-Mortensen, R. Gomis, S. Andersen, and P. Arner, “The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes,” The New England Journal of Medicine, vol. 345, no. 12, pp. 870–878, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. C. D. Stehouwer, H. R. Fischer, A. W. Van Kuijk, B. C. Polak, and A. J. Donker, “Endothelial dysfunction precedes development of microalbuminuria in IDDM,” Diabetes, vol. 44, no. 5, pp. 561–564, 1995. View at Scopus
  44. M. Nangaku, “Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure,” Journal of the American Society of Nephrology, vol. 17, no. 1, pp. 17–25, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. V. Negrean, I. Suciu, D. Sâmpelean, and A. Cozma, “Rheological changes in diabetic microangiopathy,” Romanian Journal of Internal Medicine, vol. 42, no. 2, pp. 407–413, 2004. View at Scopus
  46. H. Zhang, P. Li, F. J. Burczynski et al., “Attenuation of diabetic nephropathy in Otsuka long-evans Tokushima fatty (OLETF) rats with a combination of Chinese herbs (tangshen formula),” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 613737, 8 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. I. Cho, M. P. Mooney, and D. J. Cho, “Hemorheological disorders in diabetes mellitus,” Journal of Diabetes Science and Technology, vol. 2, no. 6, pp. 1130–1138, 2008.
  48. S. Y. Huang, C. Jeng, S. C. Kao, J. J. Yu, and D. Z. Liu, “Improved haemorrheological properties by Ginkgo biloba extract (Egb 761) in type 2 diabetes mellitus complicated with retinopathy,” Clinical Nutrition, vol. 23, no. 4, pp. 615–621, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. X. P. Liu, J. J. Luan, and C. E. Goldring, “Comparison of the antioxidant activity amongst Gingko biloba extract and its main components,” Zhong Yao Cai, vol. 32, no. 5, pp. 736–740, 2009 (Chinese). View at Scopus
  50. C. Shi, Z. Yao, J. Xu, and D. T. Yew, “Effects of Gingko Extract (EGb761) on oxidative damage under different conditions of serum supply,” Journal of Bioenergetics and Biomembranes, vol. 41, no. 1, pp. 61–69, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. A. A. Izzo and E. Ernst, “Interactions between herbal medicines and prescribed drugs: an updated systematic review,” Drugs, vol. 69, no. 13, pp. 1777–1798, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. G. B. Kudolo, “The effect of 3-month ingestion of Ginkgo biloba extract on pancreatic β-cell function in response to glucose loading in normal glucose tolerant individuals,” Journal of Clinical Pharmacology, vol. 40, no. 6, pp. 647–654, 2000. View at Scopus
  53. G. B. Kudolo, “The effect of 3-month ingestion of Ginkgo biloba extract (EGb 761) on pancreatic β-cell function in response to glucose loading in individuals with non-insulin-dependent diabetes mellitus,” Journal of Clinical Pharmacology, vol. 41, no. 6, pp. 600–611, 2001. View at Publisher · View at Google Scholar · View at Scopus
  54. G. B. Kudolo, W. Wang, R. Elrod, J. Barrientos, A. Haase, and J. Blodgett, “Short-term ingestion of Ginkgo biloba extract does not alter whole body insulin sensitivity in non-diabetic, pre-diabetic or type 2 diabetic subjects—a randomized double-blind placebo-controlled crossover study,” Clinical Nutrition, vol. 25, no. 1, pp. 123–134, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. J. L. Pedroso, C. C. Henriques Aquino, M. L. Escórcio Bezerra et al., “Ginkgo biloba and cerebral bleeding: a case report and critical review,” Neurologist, vol. 17, no. 2, pp. 89–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. K. C. Fong and P. E. Kinnear, “Retrobulbar haemorrhage associated with chronic Gingko biloba ingestion,” Postgraduate Medical Journal, vol. 79, no. 935, pp. 531–532, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Uchida, H. Yamada, X. D. Li et al., “Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers,” Journal of Clinical Pharmacology, vol. 46, no. 11, pp. 1290–1298, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. L. Fan, G. Y. Tao, G. Wang et al., “Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers,” Annals of Pharmacotherapy, vol. 43, no. 5, pp. 944–949, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. L. Fan, X. Q. Mao, G. Y. Tao et al., “Effect of Schisandra chinensis extract and Ginkgo biloba extract on the pharmacokinetics of talinolol in healthy volunteers,” Xenobiotica, vol. 39, no. 3, pp. 249–254, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. M. A. Mohutsky, G. D. Anderson, J. W. Miller, and G. W. Elmer, “Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo,” American Journal of Therapeutics, vol. 13, no. 1, pp. 24–31, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. G. B. Kudolo, W. Wang, M. Javors, and J. Blodgett, “The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects-A double blind placebo-controlled, crossover study,” Clinical Nutrition, vol. 25, no. 4, pp. 606–616, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Yoshioka, N. Ohnishi, T. Koishi et al., “Studies on interactions between functional foods or dietary supplements and medicines. IV. Effects of Ginkgo biloba leaf extract on the pharmacokinetics and pharmacodynamics of nifedipine in healthy volunteers,” Biological and Pharmaceutical Bulletin, vol. 27, no. 12, pp. 2006–2009, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. C. X. Guo, Q. Pei, J. Y. Yin et al., “Effects of Ginkgo biloba extracts on pharmacokinetics and efficacy of atorvastatin based on plasma indices,” Xenobiotica, vol. 42, no. 8, pp. 784–790, 2012.